

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Symproic (naldemedine) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 6 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Symproic (naldemedine).**Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.**

KP-MAS Formulary can be found at: Pharmacy | Community Provider Portal | Kaiser Permanente

	1 – Patient Information		
Patient Name:	Kaiser Medical ID#:	Date of Birth:	
	2 – Prescriber Information		
Prescriber Name:	Specialty:	NPI:	
Prescriber Address:			
Prescriber Phone #:	Prescriber Fax #:		
	3 – Pharmacy Information		
Pharmacy Name:	Pharmacy NPI:		
Pharmacy Phone #	Pharmacy Fax #:		
	lation:		
Jig			
Drug 2: Name/Strength/Formu	lation:		
Sig:			
1 Is this request for initia	5- Diagnosis/Clinical Criteria		
 Is this request for initia □ Initial therapy 	☐ Continuing therapy? ☐ Continuing therapy, state start date:		
	liagnosis for the requested medication:		
Clinical Criteria:			
 Prescriber is a Gastroenterologist, Oncologist, or Pain Specialist, 			

	□ No □ Yes
2.	AND member has a diagnosis of opioid induced constipation in an adult with an active opioid prescription \Box No \Box Yes
3.	AND opioid medication is being prescribed by an oncologist or a hospice/palliative care clinician for a member currently enrolled in hospice or palliative care program, or after consultation with a pain management specialist □ No □ Yes
4.	AND member has failed a trial of at least 2 weeks or has an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action (i.e., osmotiwith a stimulant) and route of administration: Polyethylene glycol Lactulose or sorbitol Senna Bisacodyl No Yes
5.	 AND member has inadequate response, contraindication or intolerance to both of the following: Generic Amitiza (lubiprostone) – 1st line Movantik – 2nd line □ No □ Yes
	tinuation of therapy, please respond to <u>additional question</u> below: Member has a positive clinical response to Symproic □ No □ Yes
	6 – Prescriber Sign-Off
Additio	nal Information –
2. If	ase submit chart notes/medical records for the patient that are applicable to this request. nember has not tried preferred agent(s) please provide rationale/explanation and any additional supporting ormation that should be taken into consideration for the requested medication:
	ry that the information provided is accurate. Supporting documentation is available for State audits.
	riber Signature: Date:
inforr	Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The lation is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, ution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not

intended for receipt by your facility